“På denne tiden, there are still access issues surrounding medicinal cannabis, with cost being one of the greatest barriers. Så, a lot of patients were hoping the referendum would pass and provide affordable access to cannabis products for wellness purposes.”
De 2020 New Zealand cannabis referendum was a non-binding referendum held on the 17th of October 2020, in the form of a vote in favour or against the “Cannabis Legalisation and Control Bill”. If the bill had passed, cannabis would have been legalized for personal use, derimot, while the official results are to be released today on November 6th, preliminary results released on October 30th, have suggested that 53.5% voted against and 46.5% of the voters cast a vote in favour.
Co-founder of Helius Therapeutics Paul Manning, said that the fact that the bill didn’t pass, will slow the establishment of the cannabis industry in New Zealand, which will in turn negatively affect patients counting on the plant for medicinal purposes.
“På denne tiden, there are still access issues surrounding medicinal cannabis, with cost being one of the greatest barriers. Så, a lot of patients were hoping the referendum would pass and provide affordable access to cannabis products for wellness purposes.” However, added Manning, while the referendum results make the situation seem dire, help is on the way.
Til denne effekten, next week on the 9th and 10th of November, New Zealand’s first medicinal cannabis conference is being held at Auckland’s Aotea Centre: MedCan Summit 2020.
The situation will improve as the cannabis industry starts establishing itself
Dess, while the current high costs on the imported products are challenging for most, the prices are expected to start settling as the local industry establishes itself. “The high cost of imported medicinal cannabis products continues to be a real challenge for patients. Heldigvis, the country’s new Medicinal Cannabis Scheme was enacted in April, giving way to the formation of a local industry. Kiwi companies are now gearing up to produce more affordable New Zealand-made cannabis medicines by mid next year,” said Manning.
“Sadly, I think we’ll now see retrenchment in some corners of the industry as a result of the referendum failing. Uansett, the country’s nascent medicinal cannabis industry will continue to grow in importance – both in public health and economic terms," han la til.
Den medisinske cannabisordningen
The Medicinal Cannabis Scheme was launched by New Zealand’s Health Ministry earlier this year. Det endelige regelverket knyttet til ordningen ble kunngjort sent i fjor, og siden da hadde Kiwi-tjenestemenn forsøkt å sikre at innehavere av forskning og utvikling var godt rustet til å ta de neste trinnene. Disse inkluderte søknad om kommersiell dyrking og produksjonstillatelser, slik at lokale selskaper er i stand til å starte produksjonen.
Lanseringen av ordningen 1. april hadde truffet virkning ganske stille, Besides having a significant impact on the many locals who are living with conditions that may be helped by the compound, the scheme will naturally also be of great benefit to the country’s economy via exporting opportunities and the multiple industries involved, which will add to the country’s GDP.
The initiative is operating via GMP (God produksjonsskikk) standarder som vil sikre kvaliteten og konsistensen av cannabinoidbaserte medisiner. Dette tjener til å forsikre leger at de foreskriver trygge produkter av høy kvalitet.
New Zealands medisinsk cannabiskonferanse: MedCan Summit 2020